Mass Tort Case Leads: A Guide to This Specific Product

Mass tort case leads represent individual, specific claim opportunities that have undergone at least preliminary factual screening, distinct from broader mass tort awareness leads.

This narrower framing typically reflects prospects further along in confirming their genuine eligibility for a specific tort category.

Understanding This Format's Position in the Funnel

Case leads typically sit further along than initial awareness contacts, having already confirmed basic factual eligibility indicators.

Why This Narrower Framing Matters

Firms evaluating case leads can expect a higher proportion of genuinely viable claims compared to broader, unscreened mass tort interest.

What Defines a Quality Case Lead

• Genuine, documented preliminary eligibility screening.
• Specific tort category confirmation.
• Documented, compliant consent for contact.
• Accurate, current contact information.

Applying Additional Firm-Level Screening

Even with preliminary screening completed, firms should apply their own additional eligibility review before formally accepting a case.

Approaching Prospects With Genuine Care

Given the genuinely serious health implications often involved, maintaining a respectful, patient approach remains essential regardless of screening depth.

Sourcing Through a Trusted Marketplace

Firms can source mass tort case leads through Eilite's buy leads platform, which applies compliance screening across its intake sources.

Measuring Conversion for This Category

Tracking cost per qualified case helps firms confirm their sourcing is genuinely producing viable claim volume.

What Preliminary Screening Typically Verifies

Preliminary factual screening for a mass tort case lead generally confirms exposure or product use, a rough timeline connecting that exposure to a specific injury or diagnosis, and basic identifying information. It does not typically replace the detailed medical record review a firm needs before formally accepting a case, but it does narrow the pool to prospects who plausibly meet the tort's basic fact pattern. This distinction matters because firms should treat this preliminary screening as a filter, not a substitute for their own diligence.

Medical Records and Documentation Collection

Once a case lead clears preliminary screening, firms typically need to collect medical records, prescription history, or other documentation establishing the factual basis for the claim. Case leads that arrive with some documentation already gathered, or with a claimant already prepared to authorize records requests, tend to move through this stage faster than leads requiring the firm to build this foundation from nothing.

Jurisdiction and MDL Considerations

Many mass tort cases consolidate into multidistrict litigation, or MDL, proceedings in federal court, while others proceed through state court systems depending on the specific tort and where claimants are located. Understanding which jurisdictional path a given case lead is likely to follow helps firms route it to the right internal team or co-counsel relationship efficiently.

Distinguishing Case Leads From Settled or Expired Tort Categories

Mass tort litigation moves through phases, active intake, settlement negotiation, and eventual close-out, and buying case leads for a tort category that's already reached settlement or whose filing deadlines have passed wastes both money and the claimant's time. Firms should confirm a lead provider's case lead volume reflects currently active, still-open tort categories rather than outdated inventory.

Pricing Considerations for Case Leads vs. Broader Awareness Leads

Because case leads have already cleared a preliminary factual screen, they typically command a higher price than broader awareness-stage leads that haven't yet confirmed basic eligibility indicators. Firms should weigh this premium against how much time and staff effort the additional screening actually saves internally, since a case lead that still requires extensive follow-up verification may not justify the higher cost over a well-run broader intake funnel.

Red Flags That Suggest Low-Quality Case Lead Sourcing

• Vague or inconsistent answers when asked exactly what screening was performed.
• Reluctance to share how leads are generated or from what sources.
• Unusually low pricing relative to the promised screening depth.
• No clear policy for handling leads that turn out to be ineligible.

Building Internal Verification Alongside Purchased Screening

Even a reputable provider's preliminary screening should be treated as a starting point, not a final answer. Firms that maintain their own internal verification checklist, covering the specific factual elements their litigation strategy actually depends on, catch mismatches that a general-purpose screening process might miss, protecting the firm from investing significant intake effort into ultimately non-viable claims.